MOTS-c vs Humanin — Two Mitochondrial-Derived Peptides Compared

Both are MDPs — but not interchangeable

MOTS-c and humanin share the mitochondrial-derived-peptide (MDP) class: both are short peptides encoded within human mitochondrial DNA rather than the nuclear genome, and both circulate as endocrine signals whose concentrations decline with age. That shared ancestry is where the similarity mostly ends. At the molecular level they are different tools built for different jobs: MOTS-c operates on the AMPK metabolic axis (Lee 2015 Cell Metab, PMID 25738459), while humanin operates on the FPRL1/FPR3 formyl-peptide-receptor family and the CNTFR/WSX-1/gp130 cytoprotective axes (Zuccato 2019, PMID 30582721). The two peptides are not competitors for the same research question; they occupy different niches in mitochondrial biology, and a researcher choosing between them should be choosing based on the biological endpoint of interest — metabolic versus cytoprotective — rather than treating them as interchangeable "mitochondrial peptides."

The two coding regions are also distinct. MOTS-c is encoded within the MT-RNR1 gene, the mitochondrial 12S rRNA locus, and was first characterised by Lee and colleagues in 2015. Humanin is encoded within the neighbouring MT-RNR2 gene, the 16S rRNA locus, and was identified considerably earlier, in work that predates the modern MDP field. Humanin also has a wider family of related short open reading frames within the same mitochondrial locus — the small humanin-like peptides (SHLPs) — that are not shared by MOTS-c, which so far has no equivalent family of paralogues described in the reference literature used on this page.

Mechanism side-by-side

MOTS-c's primary reported action is activation of AMP-activated protein kinase (AMPK), the cellular energy-sensing enzyme that shifts metabolism toward catabolic, energy-generating pathways when cellular ATP is low. Lee 2015 (PMID 25738459) reported that MOTS-c administration in animal models reduced diet-induced obesity and improved insulin resistance, with effects consistent with AMPK-pathway engagement in skeletal muscle and liver. A direct, single, high-affinity cell-surface receptor for MOTS-c has not been definitively established in the literature this page draws on — the AMPK effect appears to be the best-characterised downstream signalling event, but the immediate binding partner upstream of it remains an open research question.

Humanin's mechanism is comparatively better resolved at the receptor level. Zuccato 2019 (PMID 30582721) describes two convergent receptor systems: the formyl-peptide receptor family (FPRL1, also called FPR2, and the related FPR3), and a tripartite receptor complex built from the ciliary neurotrophic factor receptor (CNTFR), WSX-1 (the IL-27 receptor alpha chain) and gp130. Engagement of these receptors triggers intracellular survival signalling that opposes apoptosis — programmed cell death — which is why humanin's research base concentrates so heavily on tissues where cell loss under stress is the central problem: neurons in models of neurodegeneration and cardiomyocytes in models of ischaemic injury.

The practical difference for a researcher: MOTS-c's literature asks "how does this peptide change whole-body energy metabolism," while humanin's literature asks "does this peptide keep a specific, vulnerable cell alive under an acute insult." Those are different experimental designs, different endpoints, and different tissues of interest.

Evidence base — head-to-head vs single-arm

No published trial has tested MOTS-c and humanin head-to-head against each other. Every study in the reference list used on this page examines one peptide (or the MDP class generally) in isolation; there is no comparative-efficacy literature to draw a direct evidence-based ranking from. That matters for how a reader should interpret any comparison table: differences shown here are differences in what each peptide's own literature reports, not differences observed within the same experiment.

Within each peptide's own evidence base, the studies fall into the same rough categories:

• Biomarker studies — showing that circulating levels of each peptide correlate with ageing, exercise status, and (for MOTS-c specifically) metabolic health markers.
• Mechanism studies — establishing the receptor and signalling pathway for each peptide, as summarised above.
• Animal-model intervention studies — chiefly in rodents, testing whether administering the peptide changes an outcome (obesity/insulin resistance for MOTS-c; cell survival under ischaemic or degenerative stress for humanin).

Neither peptide has phase-3 clinical outcome trial data in humans. Woodhead 2021 (PMID 34520826) reviewed the exercise-responsiveness literature for the MDP class as a whole and found that MOTS-c is reliably elevated both acutely (during a single bout of exercise) and chronically (with sustained training) — a more consistent exercise signal than the one reported for humanin, whose exercise-related rise is described as smaller and less consistent across studies. For the class as a whole, the Zhou 2024 review (Diabetol Metab Syndr, PMID 39160573) is the current best synthesis and is the source this page relies on for cross-peptide, cross-study conclusions.

Clinical use cases

Neither peptide is a clinical tool with an established human use case; both remain research compounds. Within the preclinical and biomarker literature, though, the two peptides point toward different downstream research questions. MOTS-c's metabolic phenotype (Lee 2015) and its exercise-responsiveness (Woodhead 2021) place it in research contexts adjacent to insulin resistance, obesity, and exercise physiology — the kind of endpoints where AMPK-pathway engagement is directly relevant. Humanin's cytoprotective phenotype (Zuccato 2019) places it in research contexts adjacent to neurodegeneration and cardiac ischaemia — endpoints where preventing cell death under acute stress, rather than shifting systemic metabolism, is the outcome of interest. Zuccato 2019 frames humanin explicitly as a "therapeutic target" under investigation for cancer and degenerative disease, language that signals early-stage target validation rather than a compound close to clinical use.

Safety signals compared

Safety data for both peptides is limited to what the underlying animal-model and mechanistic literature reports; there is no human clinical-trial safety database for either compound, and no adverse-event profile has been established through controlled human dosing studies in the reference list this page relies on. The Zhou 2024 review notes that the MDP field overall remains at an early enough stage that systemic safety signals — beyond the acute, model-specific observations reported in individual mechanism papers — have not been characterised. Nothing in the cited literature supports a comparative safety ranking between MOTS-c and humanin; readers should not infer that either peptide has a better- or worse-established safety profile than the other based on the evidence summarised here.

Combining them

The Epitalon + humanin + MOTS-c longevity stack reviews the theoretical rationale for combining MDPs across the ageing / metabolic axis. Direct combination-evidence is limited to the Elhusseiny 2026 dexamethasone-cachexia paper referenced on that page — a narrow experimental context that does not generalise into a broad claim about combined MOTS-c/humanin use.

UK regulatory context

Both compounds are unlicensed research chemicals in the UK. Neither has an MHRA marketing authorisation, and neither has reached a licensed clinical indication anywhere, unlike some other mitochondria-related peptides (see the SS-31 vs MOTS-c comparison for a contrast with a peptide that has reached FDA approval for a narrow indication). Any promotion of MOTS-c or humanin as anti-ageing, metabolic-optimisation, or cognitive-protection products would fall under MHRA rules on advertising unlicensed medicines — see our POM advertising hub.

Verdict / Which to choose (or neither)

For a reader trying to decide which peptide's research literature is relevant to their question, the answer depends entirely on the endpoint. If the interest is metabolic — insulin sensitivity, mitochondrial biogenesis, exercise physiology — MOTS-c's evidence base (Lee 2015, Woodhead 2021) is the more directly relevant literature. If the interest is cytoprotection — cell survival under ischaemic or degenerative stress, particularly in neurons or cardiomyocytes — humanin's evidence base (Zuccato 2019) is the more directly relevant literature. Neither answer implies that one peptide is more "advanced" or better validated than the other in an absolute sense: both remain unlicensed, both lack phase-3 human outcome data, and the Zhou 2024 class-wide review is explicit that the MDP field as a whole is still early. The honest verdict is that this is not a "which is better" comparison at all — it is a "which question are you asking" comparison, and the two peptides answer different questions.

Related pages

• MOTS-c monograph
• Humanin monograph
• SS-31 monograph — mitochondria-targeted synthetic; distinct class
• SS-31 vs MOTS-c comparison
• Mitochondrial-derived peptides map
• Mitochondrial-derived peptides glossary entry

Verdict — research-question matching

Same organelle-of-origin, different molecular tools. MOTS-c is the metabolic MDP — its research base sits in insulin sensitivity, mitochondrial biogenesis, and exercise mimetic effects. Humanin is the cytoprotective MDP — its research base sits in cell survival under stress, particularly neuronal and cardiac. Neither has UK licensing. Both fields are early-stage; the combined MDP body of evidence (Zhou 2024 review) does not yet support any clinical claim in either direction.

References

Peer-reviewed sources for the claims above. Where an editor has verified study type, sample size, outcome and limitation, the citation is rendered as a card; otherwise as a plain reference. Links open PubMed or the journal DOI.

1. Lee C, Zeng J, Drew BG, et al.. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3) :443-454 doi:10.1016/j.cmet.2015.02.009 · PMID: 25738459
2. Zuccato CF, Asad AS, et al.. Mitochondrial-derived peptide humanin as therapeutic target in cancer and degenerative diseases. Expert Opinion on Therapeutic Targets. 2019;23(2) :117-126 · PMID: 30582721
3. Woodhead JST, Merry TL. Mitochondrial-derived peptides and exercise. Biochimica et Biophysica Acta. General Subjects. 2021;1865(12) :130011 · PMID: 34520826
4. Zhou Q, Kang H, et al.. The correlation between mitochondrial derived peptide (MDP) and metabolic states. Diabetology & Metabolic Syndrome. 2024;16(1) :202 · PMID: 39160573